SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia

In the first head-to-head trial of a pegylated interferon and an approved treatment for essential thrombocythemia (ET), the phase III SURPASS-ET trial will compare ropeginterferon alfa-2b versus anagrelide as second-line therapy among patients with high-risk ET. The open-label, randomized, active-controlled trial plans to analyze the efficacy, tolerability, pharmacokinetics, and safety among patients with hydroxyurea-resistant or -intolerant disease.